57 results about "Genetic signature" patented technology

A candidate single nucleotide polymorphism (SNP) combination is selected from a plurality of candidate SNP combinations for a gene associated with a genetic trait. Haplotype data associated with this candidate SNP combination are read for a plurality of individuals and grouped into a positive-responding group and a negative-responding group based on whether a predetermined trait criteria for an individual is met. A statistical analysis on the grouped haplotype data is performed to obtain a statistical measurement. The acts of selecting, reading, grouping, and performing are repeated as necessary to identity the candidate SNP combination having the optimal statistical measurement. In one approach, a directed search based on results of previous statistical analysis of SNP combinations is performed until the optimal statistical measurement is obtained. In addition, the number of SNP combinations selected and analyzed may be reduced based on a simultaneous testing procedure.

The present invention is related to the identification of cancer stem cells using the MMTV-Wnt-1 transgenic mouse model. These cancer stem cells have a gene expression signature that allows them to be distinguished from their non-tumorigenic counterparts. Moreover, the gene expression pattern can also predict survival in a diverse group of solid tumors.

The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.

A method for automatically generating a genetic signature for a set of malware, comprising parsing (step S11) the malware to identify a set of binary comparable features present in said malware, storing (step S5; step S11) all binary comparable features occurring in said set of malware, determining (step S13, S14) a subset comprising binary comparable features occurring in at least a predetermined portion of all malware in the set, and including (step S15) representations of the binary comparable features in the subset in the genetic signature.Compared to prior art systems, the genetic signature according to the present invention is unique in that it does not rely on relationships between individual features, only on their occurrence in various malware in the set. A genetic signature according to the present invention may for example consist of associations to five different features which have no relation to each other at all.

Sequencing-by-synthesis (SBS) method is provided that includes providing a detection apparatus that includes an array of magnetically-responsive sensors. Each of the magnetically-responsive sensors is located proximate to a respective designated space to detect a magnetic property therefrom. The detection apparatus also includes a plurality of nucleic acid template strands located within corresponding designated spaces. The method also includes conducting a plurality of SBS events to grow a complementary strand by incorporating nucleotides along each template strand. At least some of the nucleotides are attached to corresponding magnetic particles having respective magnetic properties. Each of the plurality of SBS events includes detecting changes in electrical resistance at the magnetically-responsive sensors caused by the respective magnetic properties of the magnetic particles. The method also includes determining genetic characteristics of the complementary strands based on the detected changes in electrical resistance.

Aspects of the present invention concern the identification of several methods to analyze the genes that are modulated in normal human bronchial epithelial (NHBE) cells after exposure to cigarette smoke condensates (CSC) or cigarette smoke (CS). Embodiments described herein include methods to identify a gene that is modulated in response to exposure to CSC or CS, methods to identify tobacco products that have a reduced potential to contribute to tobacco-related disease, methods to make tobacco products that have a reduced potential to contribute to a tobacco-related disease, methods to identify a subject's predilection to acquire a tobacco related disease, the use of particular genes as biomarkers for tobacco-related disease, and patterns of gene expression or genetic signatures that are unique to each particular tobacco product.

There is describe a biochemical method for detecting one or more genetic characteristics. The method utilizes supports (1), wherein the largest dimension (3) of each support (1) is less than 250 um and wherein each support (1) incorporates sequential identification means (2). The method is distinguished in that it includes the steps of: attaching an information molecule (7), which is capable of interacting with at least one of said one or more genetic characteristic to be detected, to a main surface (11) of a support (1); suspending supports (1) comprising one or more different sequential identifications means (2) and one or more different information molecules (7) in a fluid; adding a sample (8) to be analysed to the fluid; detecting interaction signals from supports (1) in the fluid using signal detecting means (40); and reading the sequential identification means (2) of the supports (1) which have an interaction signal using reading means (3), thereby detecting at least one of said one or more genetic characteristic (8). There is also described apparatus susceptible for use in executing the above method.

Systems and methods are provided for generating a biological signature such as a genetic signature and using such signature of an individual. The biological signature may be used to verify the identity of the individual. A verified individual may be granted access to a secured location, item, and / or service. Biological signatures may also be used to search or aggregate records for an individual.

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.

This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer.

Compositions and methods for the diagnosis and treatment of breast cancer are provided.

Technologies for assessing, quantifying and isolating sperm cell populations and / or subpopulations having specific genetic signatures are provided, as well as methods and systems to assess the efficacy of chromosomal differentiation processes. Compositions for identification and differentiation of X-chromosomes and Y-chromosomes in DNA are also provided.

Methods, compositions, and kits for identifying individuals who will be resistant to androgen deprivation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to an androgen deprivation therapy resistance signature based on expression levels of genes that are differentially expressed between responders and non-responders to androgen deprivation therapy and its use to identify individuals likely to respond poorly or be non-responsive to androgen deprivation therapy, who are in need of treatment for prostate cancer by other methods.

A computer-implemented method of comparing one or more genetic traits of two users. Each user has a wearable device storing data indicative of the one or more genetic traits, the data having been obtained by an analysis of a biological sample provided by the user. The method comprises: transmitting the data indicative of the one or more genetic traits from a first of the wearable devices to a first computer device using a short-range wireless data connection; transmitting the data from the first computer device to a second computer device over a data network; transmitting the data from the second computer device to a second of the wearable devices over a short-range wireless data connection; and comparing the data from the first wearable device with the data stored on the second wearable device to determine whether there is a match between the users' one or more genetic traits.

Genetic signatures capable of distinguishing among several types of gliomas provide clinically relevant information that can serve as an adjunct to histopathological diagnosis. For example, mutations in the TERT promoter occurred in 74.2% of glioblastomas (GBM), but occurred in a minority of Grade II-III astrocytomas (18.2%). In contrast, IDH1 / 2 mutations were observed in 78.4% of Grade II-III astrocytomas, but were uncommon in primary GBM. The genetic signatures permit the stratification of the glioma patients into distinct cohorts.

Aspects of the present invention concern the identification of several methods to analyze the genes that are modulated in normal human bronchial epithelial (NHBE) cells after exposure to cigarette smoke condensates (CSC) or cigarette smoke (CS). Embodiments described herein include methods to identify a gene that is modulated in response to exposure to CSC or CS, methods to identify tobacco products that have a reduced potential to contribute to tobacco-related disease, methods to make tobacco products that have a reduced potential to contribute to a tobacco-related disease, methods to identify a subject's predilection to acquire a tobacco related disease, the use of particular genes as biomarkers for tobacco-related disease, and patterns of gene expression or genetic signatures that are unique to each particular tobacco product.

A computer-implemented method of comparing one or more genetic traits of two users. Each user has a wearable device storing data indicative of the one or more genetic traits, the data having been obtained by an analysis of a biological sample provided by the user. The method comprises: transmitting the data indicative of the one or more genetic traits from a first of the wearable devices to a first computer device using a short-range wireless data connection; transmitting the data from the first computer device to a second computer device over a data network; transmitting the data from the second computer device to a second of the wearable devices over a short-range wireless data connection; and comparing the data from the first wearable device with the data stored on the second wearable device to determine whether there is a match between the users' one or more genetic traits.

Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic signature are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the genetic signature.

Provided herein are methods for diagnosing cardiomyopathy by evaluating a sample from a subject for the presence of a population of activated fibroblasts comprising a particular genetic signature (e.g., a genetic signature comprised of differential expression of one or more gene products relative to a normal subject or a population of normal subjects). The one or more gene products may include POSTN, COL22A1, and / or THBS4. Also provided herein are methods for treating cardiomyopathy and for modulating the activity of one or more gene products associated with activation of cardiac fibroblasts in a subject using an agent. Compositions comprising an agent for treating cardiomyopathy and kits for diagnosing cardiomyopathy are also provided by the present disclosure.

The invention provides a fluorescence detection kit based on a Y-STR gene locus and Y-Indel as well as a use method and application of the fluorescence detection kit. The fluorescence detection kit can be used for simultaneously analyzing 38 Y-STR gene loci and 3 Y-indel in a single PCR. According to the kit, a multicolor fluorescence labeling composite amplification technology is adopted, amplification can be rapidly completed, a unique locus combination mode and a primer sequence better conform to the genetic characteristics of Chinese people, enough universal loci are reserved, exchange and sharing of DNA data are facilitated, and the kit better conform to the genetic characteristics of Chinese people; meanwhile, an amplification product is stable and long-acting, the Y chromosome specificity is high, complete male DNA typing can still be obtained under the high-background female DNA condition, and the method is suitable for extracting samples such as DNA, blood spots, saliva spots and oral swabs and can be used for multiple purposes such as paternal genetic relationship identification, individual recognition and public security library building.

Disclosed are genetic methods and tools for colon cancer disease classification in disease subtypes, CMS1, CMS2, CMS3, CMS4, as well as improved methods for rapid, more accurate, and more reliably reproducible disease subtype determination. Tailored treatment protocols are also provided, employing the predicted CMS of the subject sample. Genetic sequence binding targets for some or all of these gene panels may be affixed to a solid substrate, and included as part of a screening tool and / or diagnostic kit. The expression levels of the genes may be assessed to provide a genetic signature for a subtype or lack of subtype (CMS1, CMS2, CMS3, CMS4, combination subtype). The methods employ a scoring system, wherein a score is derived from the genetic expression profile / signature of the panel of selected genes, and a qualifying continuous score for each CMS subtype is determined against a predictive threshold for each colon cancer subtype.

The invention relates to the technical field of gene physical examination, and discloses an automatic gene physical examination report generation method and system. The system comprises a gene data acquisition module, a gene data analysis processing module, a gene data storage module, a gene typing information and phenotype database module, a phenotype description and guidance suggestion databasemodule, a gene physical examination report content customizing module and a report generation module. According to the method, various phenotypes and health conditions of individuals are analyzed fromthe gene level, the phenotypes cover disease risks, individual genetic characteristics, accurate medication guidance and the like, and the issued report is suitable for various scenes and high in applicability; the population distribution specificity of the genetic typing information, the phenotypic database and the SNP typing frequency using background data is obvious, so that the method is morereasonable and accurate, and the technicality is ensured; the report content supports self-definition and can be selected and adjusted according to requirements, so that the actual application scenecan be better met; meanwhile, the method provided by the invention is automatically controlled by a computer, the report generation link is simplified, the labor cost is reduced, and the report generation efficiency is improved.

A gene panel comprising genes regulated in mammalian skin in response to generation of a radio frequency current in a tissue volume of the mammalian skin sufficient to heat the tissue volume to a treatment temperature, wherein at least one gene is selected from Table 1 or Table 2 and at least one gene is selected from Table 3. Further there is a method for providing a benefit to mammalian skin, the benefit comprising inducing collagen formation and / or dermal remodeling in a dermal layer of the mammalian skin in the absence of a skin-damaging inflammatory cytokine response, the method comprising generating a radio frequency current in a tissue volume of the mammalian skin for a treatment cycle sufficient to heat the tissue volume to a treatment temperature while avoiding an upregulation in expression of genes listed in Table 3.